Baxter International Inc (BAX) 44.49 $BAX
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), HAE: 29.58 (-0.14), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 20.63 (-0.36), BAX: 44.49 (-0.26)
Hill-Rom: Welch-Allyn Buyout Drives Q2, Forex Woes Stay
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:20AM CDT
Hill-Rom (HRC) posted a mixed second quarter of fiscal 2016 with the bottom line surpassing the Zacks Consensus Estimate and the top line missing the same.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HRC: 50.10 (-1.12)
Hologic: Q2 Strong on Segmental Expansion, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:43AM CDT
Hologic (HOLX) ended second-quarter fiscal 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HOLX: 34.14 (-0.81)
CVS Health (CVS): Strong Q1, Mega Buyouts Offer Hope
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:24AM CDT
On Jun 7, 2016, we issued an updated research report on CVS Health Corp. (CVS).
BSX: 23.02 (-0.30), HLF: 61.89 (-0.55), BAX: 44.49 (-0.26), CVS: 96.67 (-0.32)
NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), BAX: 44.49 (-0.26), NUVA: 58.98 (-1.03)
United States Syringes and Needles Market Outlook to 2021 - Key Players are Nipro Corporation, Baxter International & Smiths Medical - Research and Markets
BusinessWire - Tue Jun 07, 3:48AM CDT
Research and Markets has announced the addition of the "United States Syringes and Needles Market Outlook to 2021" report to their offering.
BAX: 44.49 (-0.26)
Why the Earnings Streak Will Continue for Baxter International (BAX)
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:49AM CDT
Baxter International (BAX) currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
BAX: 44.49 (-0.26)
Mead Johnson: Strong Q1 on Overseas Growth & Strategies
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 6:40AM CDT
Mead Johnson (MJN) embarked on a promising journey this year, posting square beats in the first quarter.
BSX: 23.02 (-0.30), MJN: 83.79 (-0.38), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Henry Schein: Q1 Results Strong, Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:02AM CDT
Henry Schein (HSIC)made an impressive start to 2016, with its top and bottom line beating the Zacks Consensus Estimate in the first quarter.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HSIC: 178.35 (-2.36)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
Medical Instruments and Supplies Industry's Stocks Get Research Review
ACCESSWIRE - Thu Jun 02, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Instruments and Supplies industry. Companies recently under review include Baxter Intl., Skyline Medical, TransEnterix, and DENTSPLY Intl. Register with us now for your free membership and see our complete reports on these equities at:
SKLN: 0.18 (+0.05), BAX: 44.49 (-0.26), TRXC: 1.45 (+0.01), XRAY: 63.61 (-0.82)
Adeptus Health Lifts Full-Year Guidance, Provides Q2 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:14AM CDT
Adeptus Health Inc. (ADPT) recently updated its full-year 2016 guidance.
AIRM: 36.18 (-0.92), BAX: 44.49 (-0.26), AHS: 39.97 (-1.01), ADPT: 51.55 (-2.57)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), GNC: 25.65 (-0.52)
Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), TMO: 151.80 (-2.35), BAX: 44.49 (-0.26), FEIC: 106.75 (-0.48)
Is Cooper Companies (COO) Poised for Q2 Earnings Beat?
Zacks Equity Research - Zacks Investment Research - Tue May 31, 6:53AM CDT
The combination of Cooper Companies' (COO) Zacks Rank #2 and +1.04% ESP makes us reasonably confident of an earnings beat.
JNJ: 117.01 (+0.01), BAX: 44.49 (-0.26), PFE: 35.29 (-0.02), COO: 163.24 (-1.96)
IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), IDXX: 88.88 (-1.37)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), CPHD: 28.27 (-0.60)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), QGEN: 21.71 (-0.49)
Global Septic Shock Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Baxter International, BTG, Bayer - Research and Markets
BusinessWire - Thu May 26, 1:29PM CDT
Research and Markets has announced the addition of the "Septic Shock Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
BAX: 44.49 (-0.26)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), HAE: 29.58 (-0.14), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 20.63 (-0.36), BAX: 44.49 (-0.26)
Hill-Rom: Welch-Allyn Buyout Drives Q2, Forex Woes Stay
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:20AM CDT
Hill-Rom (HRC) posted a mixed second quarter of fiscal 2016 with the bottom line surpassing the Zacks Consensus Estimate and the top line missing the same.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HRC: 50.10 (-1.12)
Hologic: Q2 Strong on Segmental Expansion, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:43AM CDT
Hologic (HOLX) ended second-quarter fiscal 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HOLX: 34.14 (-0.81)
CVS Health (CVS): Strong Q1, Mega Buyouts Offer Hope
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:24AM CDT
On Jun 7, 2016, we issued an updated research report on CVS Health Corp. (CVS).
BSX: 23.02 (-0.30), HLF: 61.89 (-0.55), BAX: 44.49 (-0.26), CVS: 96.67 (-0.32)
NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), BAX: 44.49 (-0.26), NUVA: 58.98 (-1.03)
United States Syringes and Needles Market Outlook to 2021 - Key Players are Nipro Corporation, Baxter International & Smiths Medical - Research and Markets
BusinessWire - Tue Jun 07, 3:48AM CDT
Research and Markets has announced the addition of the "United States Syringes and Needles Market Outlook to 2021" report to their offering.
BAX: 44.49 (-0.26)
Why the Earnings Streak Will Continue for Baxter International (BAX)
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:49AM CDT
Baxter International (BAX) currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
BAX: 44.49 (-0.26)
Mead Johnson: Strong Q1 on Overseas Growth & Strategies
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 6:40AM CDT
Mead Johnson (MJN) embarked on a promising journey this year, posting square beats in the first quarter.
BSX: 23.02 (-0.30), MJN: 83.79 (-0.38), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Henry Schein: Q1 Results Strong, Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:02AM CDT
Henry Schein (HSIC)made an impressive start to 2016, with its top and bottom line beating the Zacks Consensus Estimate in the first quarter.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HSIC: 178.35 (-2.36)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
Medical Instruments and Supplies Industry's Stocks Get Research Review
ACCESSWIRE - Thu Jun 02, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 2, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Instruments and Supplies industry. Companies recently under review include Baxter Intl., Skyline Medical, TransEnterix, and DENTSPLY Intl. Register with us now for your free membership and see our complete reports on these equities at:
SKLN: 0.18 (+0.05), BAX: 44.49 (-0.26), TRXC: 1.45 (+0.01), XRAY: 63.61 (-0.82)
Adeptus Health Lifts Full-Year Guidance, Provides Q2 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:14AM CDT
Adeptus Health Inc. (ADPT) recently updated its full-year 2016 guidance.
AIRM: 36.18 (-0.92), BAX: 44.49 (-0.26), AHS: 39.97 (-1.01), ADPT: 51.55 (-2.57)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), GNC: 25.65 (-0.52)
Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), TMO: 151.80 (-2.35), BAX: 44.49 (-0.26), FEIC: 106.75 (-0.48)
Is Cooper Companies (COO) Poised for Q2 Earnings Beat?
Zacks Equity Research - Zacks Investment Research - Tue May 31, 6:53AM CDT
The combination of Cooper Companies' (COO) Zacks Rank #2 and +1.04% ESP makes us reasonably confident of an earnings beat.
JNJ: 117.01 (+0.01), BAX: 44.49 (-0.26), PFE: 35.29 (-0.02), COO: 163.24 (-1.96)
IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), IDXX: 88.88 (-1.37)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), CPHD: 28.27 (-0.60)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), QGEN: 21.71 (-0.49)
Global Septic Shock Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Baxter International, BTG, Bayer - Research and Markets
BusinessWire - Thu May 26, 1:29PM CDT
Research and Markets has announced the addition of the "Septic Shock Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
BAX: 44.49 (-0.26)
